BOSTON - Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced preclinical data for MRT-55811, a molecular glue degrader targeting cyclin E1 (CCNE1), according to a press release statement. The announcement comes as shares have surged over 330% in the past year, with the stock trading at $19.78 and delivering a 13% return in just the last week, according to InvestingPro data.
The company presented data at the American Association for Cancer Research Annual Meeting 2026 on Monday. MRT-55811 induced tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers.
The compound demonstrated degradation of CCNE1 with no detectable degradation of related cyclins or cyclin-dependent kinases. In CCNE1-amplified cancer cell lines, MRT-55811 selectively inhibited cellular proliferation while sparing cell lines without amplification.
Kinome profiling and genetic modeling showed MRT-55811 exhibited superior selectivity compared to clinical-stage CDK2 inhibitors, which showed significant off-target activity.
"MRT-55811 also exhibited superior selectivity when compared to clinical-stage CDK2 inhibitors, suggesting that our CCNE1-directed MGDs could avoid the dose-limiting toxicities reported for these less selective agents," said Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics.
The positive preclinical data has attracted analyst attention, with three analysts recently revising their earnings estimates upward and the consensus recommendation standing at strong buy. The company currently holds a market capitalization of $1.58 billion. InvestingPro analysis indicates the stock is trading above its Fair Value, placing it among overvalued stocks in the biotech sector.
In vivo studies showed MRT-55811 monotherapy resulted in tumor regression and pathway suppression in multiple CCNE1-amplified models. The compound downmodulated retinoblastoma protein phosphorylation and E2F-driven gene expression in tumors grown in vivo.
CCNE1 is amplified or overexpressed across multiple cancer types, including ovarian, endometrial, gastric, and breast cancers. Monte Rosa's CCNE1-directed molecular glue degraders selectively degrade the cyclin E1/CDK2 holoenzyme complex while sparing other proteins.
The company anticipates submitting an Investigational New Drug application for the program later this year.
Monte Rosa is a clinical-stage biotechnology company developing molecular glue degrader medicines with three programs currently in clinical trials.
In other recent news, Monte Rosa Therapeutics reported positive trial data for its prostate cancer drug MRT-2359, in combination with enzalutamide. The Phase 1/2 study revealed a 100% PSA response rate and a 100% disease control rate among patients with androgen receptor mutations. This included two patients with partial responses and three with stable disease, all showing a reduction in target lesion size. Additionally, Monte Rosa announced that three of its programs, NEK7, GSPT1, and VAV1, are advancing into several Phase 2 studies this year.
In terms of analyst activity, Jefferies lowered its price target for Monte Rosa shares to $30 from $31 but maintained a Buy rating, viewing the company as more than just a degrader story. Similarly, Guggenheim reduced its price target to $30 from $34, citing dilution, but also kept a Buy rating. These recent developments highlight the ongoing interest and activity surrounding Monte Rosa's clinical progress and financial outlook.